{"entity":{"id":"martin-schlumberger","kind":"person","name":"Martin Schlumberger","aka":[],"tldr":"Led SELECT (lenvatinib) and the ESTIMABL trials that showed many thyroid cancer patients can have lower radioiodine doses or none at all.","summary":"Martin Schlumberger was principal investigator of SELECT, which established lenvatinib for radioiodine-refractory differentiated thyroid cancer, and led ESTIMABL1 and ESTIMABL2, the French trials showing that low-dose radioiodine, and for low-risk patients no radioiodine, are non-inferior to standard ablation, sharply de-escalating thyroid cancer treatment. He has chaired the European Thyroid Association and ATA guideline work.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schlumberger%20M%5BAuthor%5D%20thyroid"}],"tags":["thyroid","radioiodine","de-escalation"],"related":[],"cancers":["thyroid"],"sections":[],"technologies":["radioligand-therapy","kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":["select-lenvatinib","estimabl2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Oncology, Gustave Roussy and Université Paris-Saclay","institutionId":"gustave-roussy","specialisms":["Thyroid cancer","Radioiodine therapy","Kinase inhibitors","Nuclear medicine"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schlumberger%20M%5BAuthor%5D%20thyroid"}],"papers":[{"title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer (SELECT)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1406470"},{"title":"Thyroidectomy without radioiodine in patients with low-risk thyroid cancer (ESTIMABL2)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2111953"},{"title":"Strategies of radioiodine ablation in patients with low-risk thyroid cancer (ESTIMABL1)","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1108586"}]},"route":"/people/martin-schlumberger/","neighbours":{"cancer":[{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"trial":[{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/"},{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/"}]}}